Monoclonal antibodies with enhanced ADCC function

Patent metadata

Field	Value
Publication number	US-9718890-B2
Application number	US-201514676508-A
Country	US
Kind code	B2
Filing date	Apr 1, 2015
Priority date	Apr 12, 2000
Publication date	Aug 1, 2017
Grant date	Aug 1, 2017

Abstract

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

First claim

What is claimed is:

1. A cell culture producing monoclonal antibodies having on the Fey glycosylation site (Asn 297, EU numbering) bi-antennary glycan structures, wherein said glycan structures of the monoclonal antibodies have a fucose content less than 55%, and wherein said monoclonal antibodies are IgG antibodies directed against an antigen and activate effector cells expressing Fcγ type III receptors.

2. The cell culture of claim 1 , wherein the fucose content is less than 50%.

3. The cell culture of claim 2 , wherein the fucose content is less than 40%.

4. The cell culture of claim 1 , wherein the monoclonal antibodies cause lysis of target cells presenting the antigen greater than 60% of lysis caused by polyclonal antibodies directed against the antigen.

5. The cell culture of claim 4 , wherein the antigen is rhesus D.

6. The cell culture of claim 1 , wherein the monoclonal antibodies cause lysis of target cells presenting the antigen greater than 90% of lysis caused by polyclonal antibodies directed against the antigen.

7. The cell culture of claim 1 , wherein the antigen is rhesus D.

8. The cell culture of claim 1 , wherein the monoclonal antibodies are IgG1 antibodies.

9. The cell culture of claim 1 , wherein the monoclonal antibodies are IgG3 antibodies.

10. The cell culture of claim 1 , wherein said glycan structures of the monoclonal antibodies have a sialic acid content of less than 25%.

11. The cell culture of claim 1 , wherein the cell culture comprises a clone produced by transfection of a cell line with a gene coding for said monoclonal antibodies.

12. The cell culture of claim 11 , wherein the cell culture comprises a clone produced by transfection of a cell line deposited with the ATCC as accession number CRL-1662.

13. The cell culture of claim 1 , wherein the cell culture comprises a clone isolated from a cell line transfected with a gene coding for said monoclonal antibodies.

14. The cell culture of claim 13 , wherein the cell culture comprises a clone isolated from a cell line deposited with the ATCC as accession number CRL-1662 transfected with a gene coding for said monoclonal antibodies.

15. The cell culture of claim 1 , wherein the fucose content is between 20% and 55%.

16. The cell culture of claim 1 , wherein the fucose content is between 25% and 55%.

17. The cell culture of claim 15 , wherein the fucose content is between 20% and 30%.

18. The cell culture of claim 16 , wherein the fucose content is between 25% and 30%.

19. The cell culture of claim 1 , wherein the antigen is an infectious disease antigen.

20. The cell culture of claim 1 , wherein the antigen is a cancer antigen.

Assignees

• Lab Francais Du Fractionnement

Inventors

• Beliard Roland
• Bourel Dominique
• Glacet Arnaud
• De Romeuf Christophe
• Bihoreau Nicolas
• Nony Emmanuel

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P31/12

  Antivirals · CPC title